Development and initial validation of an updated version of the British Isles Lupus Assessment Group ’ s disease activity index for patients with systemic lupus erythematosus

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Not labeled

• Identifiers

  No identifiers available.

• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Past, present--and future?

  2005cited by this paper
• International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease.

  2004influential reference
• Definition and treatment of lupus flares measured by the BILAG index.

  2003influential reference
• An analysis of clinical disease activity and nephritis-associated serum autoantibody profiles in patients with systemic lupus erythematosus: a cross-sectional study.

  2001cited by this paper
• From BILAG to BLIPS—disease activity assessment in lupus past, present and future

  2000cited by this paper
• The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes.

  1999cited by this paper
• Long-term follow-up of autoantibody profiles in black female lupus patients and clinical comparison with Caucasian and Asian patients.

  1997cited by this paper
• The occurrence, nature and distribution of flares in a cohort of patients with systemic lupus erythematosus: a rheumatological view.

  1995influential reference
• The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus.

  1993cited by this paper
• Intraclass correlations: uses in assessing rater reliability.

  1979cited by this paper

• Long Term Outcomes of Anti-COVID-19 Vaccines in Patients with Systemic Lupus Erythematosus: A Multicentre Study

  2025cites this paper
• Stratifying patients by TNFSF13B genotype revealed increased flare and renal flare risk, but a greater benefit from belimumab: a potential biomarker for personalized treatment in systemic lupus erythematosus.

  2025cites this paper
• Design of Two Randomized, Placebo-Controlled, Phase 3 Trials of Deucravacitinib, an Oral, Selective, Allosteric TYK2 Inhibitor, in Systemic Lupus Erythematosus

  2025cites this paper
• Concomitant Lupus Enteritis and Lupus Cystitis: Case Report and Literature Review

  2025cites this paper
• Association of Blood–Brain Barrier Function With Disease Activity and Cognitive Function in Systemic Lupus Erythematosus Patients

  2025cites this paper
• Long-Term Safety of Anti-COVID-19 mRNA Vaccines in Patients with Systemic Lupus Erythematosus and Lupus-like Diseases with a Previous History of Myocarditis

  2025cites this paper
• Biomarkers in Lupus Nephritis: An Evidence-Based Comprehensive Review

  2025cites this paper
• Preliminary safety and efficacy of relmacabtagene autoleucel (relma-cel) in adults with moderately to severely active systemic lupus erythematosus: a phase I dose-escalation study.

  2025cites this paper
• B cell depletion and BAFF receptor blockade with ianalumab (VAY736) for the treatment of moderate-to-severe systemic lupus erythematosus: a phase 2 randomised, double-blind, placebo-controlled trial with subsequent open-label treatment.

  2025cites this paper
• Prediction of Lupus Classification Criteria via Generative AI Medical Record Profiling

  2025cites this paper
• Serum untargeted metabolomics alterations in systemic lupus erythematosus patients with elevated serum ferritin

  2025cites this paper
• Advances in the treatment of systemic lupus erythematosus

  2025cites this paper
• Usefulness of Belimumab in Adult Patients With Systemic Lupus Erythematosus Evaluated Using Single Indexes: A Meta-Analysis and Systematic Review

  2024cites this paper
• ĐÁNH GIÁ ĐẶC ĐIỂM CHẤT LƯỢNG MÔ DÂY RỐN THU THẬP TẠI BỆNH VIỆN BƯU ĐIỆN

  2024cites this paper
• Dealing with Lupus (SLE) and nursing intervention plan: An updated review

  2024cites this paper
• Cognitive impairment in a Colombian cohort of patients with systemic lupus erythematosus: A cross-sectional study

  2024cites this paper
• Metabolic alterations in vitamin D deficient systemic lupus erythematosus patients

  2024cites this paper
• Organ damage in Systemic Lupus Erythematosus patients: A multifactorial phenomenon.

  2023cites this paper
• Performance of systemic lupus erythematosus responder index for detecting clinician‐rated responders in patients with active systemic lupus erythematosus

  2023cites this paper
• Complement as a Biomarker for Systemic Lupus Erythematosus

  2023cites this paper
• Deconvolution of whole blood transcriptomics identifies changes in immune cell composition in patients with systemic lupus erythematosus (SLE) treated with mycophenolate mofetil

  2023cites this paper
• Lupus enteritis: A 10-year experience in a single Latin American center

  2023cites this paper
• SLE-BRAVE I and II.

  2023cites this paper
• Which extra-renal flare is "difficult to treat" in systemic lupus erythematosus? A one-year longitudinal study comparing traditional and machine learning approaches.

  2023cites this paper
• The influence of intrathecal injection of methotrexate and dexamethasone on neuropsychiatric systemic lupus erythematosus (NPSLE): a retrospective cohort study of 386 patients with NPSLE

  2023cites this paper
• Adaptation of the Russian version of the activity index of systemic lupus erythematosus EASY-BILAG

  2023cites this paper
• Tracking of Systemic Lupus Erythematosus (SLE) Longitudinally Using Biosensor and Patient-Reported Data: A Report on the Fully Decentralized Mobile Study to Measure and Predict Lupus Disease Activity Using Digital Signals—The OASIS Study

  2023cites this paper
• Evaluation of the LFA-REAL clinician-reported outcome (ClinRO) and patient-reported outcome (PRO): prespecified analysis of the phase III ustekinumab trial in patients with SLE

  2023cites this paper
• Real-World Effectiveness of Belimumab in Patients with Active Lupus

  2023cites this paper
• 50th Year of Publication: Exploring Advances in Rheumatology in the 2000s

  2023cites this paper
• Assessment of disease activity and damage in SLE: Are we there yet?

  2023cites this paper
• Performance of a New Instrument for the Measurement of Systemic Lupus Erythematosus Disease Activity: The SLE-DAS

  2023cites this paper
• Lupus Nephritis With Collapsing Glomerulopathy: A Rare Association

  2023cites this paper
• Musculoskeletal manifestations of systemic lupus erythematosus.

  2023cites this paper
• Promising Experimental Treatments for Lupus Nephritis: Key Talking Points and Potential Opportunities

  2023cites this paper
• Burden of lupus activity on health care resources utilization in Buenos Aires, Argentina

  2023cites this paper
• What is the best instrument to measure disease activity in SLE? - SLE-DAS vs easy BILAG.

  2023cites this paper
• Cost-effectiveness analysis of anifrolumab therapy in patients with systemic lupus erythematosus in the Russian Federation

  2023cites this paper
• Validation and the associated factors of the Malay version of systemic lupus erythematosus-specific health-related quality of life questionnaires (SLEQoL and LupusQoL)

  2023cites this paper
• Assessment-Tools für den systemischen Lupus erythematodes

  2023cites this paper
• Advances in the Pathogenesis and Treatment of Systemic Lupus Erythematosus

  2023cites this paper
• A Practical Overview of the Articular Manifestations of Systemic Lupus Erythematosus

  2023cites this paper
• Proteomic analysis identifies subgroups of patients with active systemic lupus erythematosus

  2023cites this paper
• Métricas em reumatologia pediátrica

  2022cites this paper
• Extent of vascular plaque predicts future cardiovascular events in patients with systemic lupus erythematosus

  2022cites this paper
• IGFBP2 function as a novel biomarker for active lupus nephritis

  2022cites this paper
• miR-374a-5p regulates inflammatory genes and monocyte function in patients with inflammatory bowel disease

  2022cites this paper
• Systemic lupus erythematosus: overview, management and COVID-19.

  2022cites this paper
• Safety and efficacy of telitacicept in refractory childhood-onset systemic lupus erythematosus: A self-controlled before–after trial

  2022cites this paper
• RNASE2 Mediates Age-Associated B Cell Expansion Through Monocyte Derived IL-10 in Patients With Systemic Lupus Erythematosus

  2022cites this paper
• Improving measures of disease activity in systemic lupus erythematosus

  2022influential citation
• Methods of assessment of joint involvement in various systemic connective tissue diseases

  2022cites this paper
• Who will respond to type I interferon receptor blockade in SLE?

  2022cites this paper
• The efficacy and safety of telitacicept for the treatment of systemic lupus erythematosus: a real life observational study

  2022cites this paper
• Gene Expression and Autoantibody Analysis Revealing Distinct Ancestry‐Specific Profiles Associated With Response to Rituximab in Refractory Systemic Lupus Erythematosus

  2022cites this paper
• Serum IFNα2 levels are associated with disease activity and outperform IFN-I gene signature in a longitudinal childhood-onset SLE cohort

  2022cites this paper
• Cell-type-specific transcriptome architecture underlying the establishment and exacerbation of systemic lupus erythematosus

  2022cites this paper
• Glucocorticoid tapering and associated outcome in patients with newly diagnosed systemic lupus erythematosus: the real-world GULP prospective observational study

  2022cites this paper
• Safe Introduction of Hydroxychloroquine Focusing on Early Intolerance Due to Adverse Drug Reactions in Patients with Systemic Lupus Erythematosus

  2022cites this paper
• Letter in reply: indirect treatment comparison of anifrolumab efficacy versus belimumab in adults with systemic lupus erythematosus

  2022cites this paper
• The Impact of Anti-SARS-CoV-2 Vaccine in Patients with Systemic Lupus Erythematosus: A Multicentre Cohort Study

  2022cites this paper
• Major determinants of prolonged remission in systemic lupus erythematosus: retrospective study over a 41-year period.

  2022cites this paper
• Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase II, Randomized, Double‐Blind, Placebo‐Controlled Trial

  2022cites this paper
• Sirolimus versus tacrolimus for systemic lupus erythematosus treatment: results from a real-world CSTAR cohort study

  2022cites this paper
• Conceptual framework for defining disease modification in systemic lupus erythematosus: a call for formal criteria

  2022cites this paper
• Agranulocytosis in systemic lupus erythematosus: A case report

  2022cites this paper
• Residual disease activity and treatment intensification in systemic lupus erythematosus: A cross-sectional study to quantify the need for new therapies

  2022cites this paper
• Trial of Anti-BDCA2 Antibody Litifilimab for Systemic Lupus Erythematosus.

  2022cites this paper
• Real world treatment of juvenile-onset systemic lupus erythematosus: Data from the UK JSLE cohort study.

  2022cites this paper
• A Contemporary Update on the Diagnosis of Systemic Lupus Erythematosus

  2022cites this paper
• Associations of improvement in laboratory tests with clinical outcomes in patients with active systemic lupus erythematosus: a multinational longitudinal cohort study.

  2022cites this paper
• Cardiac Safety of mRNA-based Vaccines in Patients with Systemic Lupus Erythematosus and Lupus-like Disorders with a History of Myocarditis

  2022cites this paper
• Distinct transcriptome architectures underlying lupus establishment and exacerbation.

  2022cites this paper
• Clinical trials in systemic lupus erythematosus: the dilemma—Why have phase III trials failed to confirm the promising results of phase II trials?

  2022cites this paper
• Longitudinal analysis of urinary proteins in lupus nephritis - A pilot study.

  2022cites this paper
• Development of a claims-based flare algorithm for systemic lupus erythematosus

  2022cites this paper
• Chronic glucocorticoid maintenance treatment is associated with the risk of SARS-CoV-2 infection in patients with systemic lupus erythematosus who received vaccination

  2022cites this paper
• B cell-targeted therapies in systemic lupus erythematosus.

  2022cites this paper
• Easy-BILAG: as easy as ABC?

  2022cites this paper
• Urinary complement proteins are increased in children with IgA vasculitis (Henoch-Schönlein purpura) nephritis

  2022cites this paper
• Clinical and laboratorial outcome of different age-onset systemic lupus erythematosus patients in Jiangsu, China: a multicentre retrospective study

  2022cites this paper
• 2022 Systemic lupus erythematosus remission in clinical practice. Message for Polish rheumatologists

  2022cites this paper
• Long-Term Clinical Outcome in Systemic Lupus Erythematosus Patients Followed for More Than 20 Years: The Milan Systemic Lupus Erythematosus Consortium (SMiLE) Cohort

  2022cites this paper
• Comparative efficacy and safety of mizoribine and mycophenolate mofetil for treating systemic lupus erythematosus: a retrospective cohort study

  2022cites this paper
• Patient and Physician Global Assessments of Disease Status in Systemic Sclerosis

  2022cites this paper
• Phase 3, multicentre, randomised, placebo-controlled study evaluating the efficacy and safety of ustekinumab in patients with systemic lupus erythematosus

  2022cites this paper
• Two clusters of systemic lupus erythematosus patients with muscle involvement in a Chinese cohort

  2022cites this paper
• Indian SLE Inception cohort for Research (INSPIRE): the design of a multi-institutional cohort

  2021cites this paper
• Emerging B-Cell Therapies in Systemic Lupus Erythematosus

  2021cites this paper
• Total plaque area and plaque echogenicity are novel measures of subclinical atherosclerosis in patients with systemic lupus erythematosus.

  2021influential citation
• Lupus or not? SLE Risk Probability Index (SLERPI): a simple, clinician-friendly machine learning-based model to assist the diagnosis of systemic lupus erythematosus

  2021cites this paper
• Comparison of Acquired Activated Protein C Resistance, Using the CAT and ST-Genesia® Analysers and Three Thrombin Generation Methods, in APS and SLE Patients

  2021cites this paper
• Clinical disease activity and flare in SLE: Current concepts and novel biomarkers.

  2021cites this paper
• The Concept of Co-Stimulatory Blockade in SLEplease remove Aff4

  2021cites this paper
• Metrics in Disease Activity Measures in Systemic Lupus Erythematosus

  2021cites this paper
• Kidney disease

  2021cites this paper
• Efficacy and Safety of Ustekinumab in Patients With Active Systemic Lupus Erythematosus: Results of a Phase II Open-label Extension Study

  2021cites this paper
• Introduction: Metrics and Domains Measured in SLE

  2021cites this paper
• Hydroxychloroquine versus tacrolimus for the treatment of persistently active systemic lupus erythematosus.

  2021cites this paper
• Clinical Aspects of Systemic Lupus Erythematosus

  2021cites this paper